Oridonin, an ingredient used in traditional Chinese medicine, has been demonstrated to play an important role in antitumour effects, but the mechanism underlying its antitumour properties is still not clear. To verify the anti-cancer effects of oridonin via a miRNA-dependent mechanism, a team of scientists led by researchers from Zhejiang Chinese Medical University performed comprehensive miRNA expression profiling of oridonin-treated BxPC-3 human pancreatic cancer cells using LC Sciences’ miRNA microarray service based on Sanger miR-Base Release 20. This was followed by validation using real-time PCR. MicroRNA target prediction and Gene Ontology and KEGG pathway analysis were performed to investigate possible pathways involved. Results showed that 105 miRNAs were significantly differentially expressed (signal reading >500, p ≤ 0.01, |Log2-value| ≥1) in oridonin-treated BxPC-3 human pancreatic cancer cells. The data in this article indicates that oridonin inhibits BxPC-3 cells probably through regulating the expression of miRNAs. Interruption of miRNA profiling may provide new therapeutic methods for the clinical treatment of pancreatic cancer.
miRNA Microarray Service – LC Sciences provides a microRNA (miRNA) expression profiling service using microarrays based on our in-house developed µParaflo® technology platform. We have standard arrays for all mature miRNAs of all species available in the latest version of the miRBase database (Release 21, July 2014). Our service is comprehensive and includes sample labeling, array hybridization, image data processing and in-depth data analysis. Two-three weeks after receiving your total RNA samples, we’ll send you both the raw and fully analyzed data. [Learn more…]
Z. Gui, S. Li, X. Liu, B. Xu, J. Xu (2015) Oridonin alters the expression profiles of MicroRNAs in BxPC-3 human pancreatic cancer cells BMC Complementary and Alternative Medicine 15:117 doi: 10.1186/s12906-015-0640-5 [article]